Atjaunināt sīkdatņu piekrišanu

Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions [Hardback]

  • Formāts: Hardback, 226 pages, weight: 592 g
  • Izdošanas datums: 03-Jun-2008
  • Izdevniecība: Demos Medical Publishing
  • ISBN-10: 1933864346
  • ISBN-13: 9781933864341
Citas grāmatas par šo tēmu:
  • Formāts: Hardback, 226 pages, weight: 592 g
  • Izdošanas datums: 03-Jun-2008
  • Izdevniecība: Demos Medical Publishing
  • ISBN-10: 1933864346
  • ISBN-13: 9781933864341
Citas grāmatas par šo tēmu:
Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of this cutting-edge extension in cancer therapy for radiation oncologists. It provides a general overview of targeted agents, reviews current clinical trials, and includes a look at the future of this state-of-the-art practice.

Over the past few years, several anti-cancer chemical agents have been developed that target specific molecules of malignant transformation. Here researchers explain how these can be combined with radiation therapy to suppress tumors for effectively. Their topics include epidermal growth factor receptors, radio-labeled monoclonal antibody therapies, targeted therapies in head and neck cancer, and cervical cancer. Annotation ©2008 Book News, Inc., Portland, OR (booknews.com)

"Radiotherapy plays an integral role in cancer treatment. Approximately 60% of cancer patients will receive radiotherapy at some point in their treatment. A major improvement in patient outcomes occurs with the use of combined chemotherapy and radiotherapy. The combination of targeted biological agents with radiotherapy is the latest cutting-edge extension in cancer therapy for radiation oncologists.

Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of the current state of clinical and pre-clinical research in combining radiotherapy with targeted biological agents to fight cancer. The text provides a general overview of targeted agents, reviews the current clinical trials, and includes a look at the future of this state-of-the-art practice.

This book begins with a general overview of the topic, including an introduction to the subject the basic science rationale behind the two most important current targeted agents: epidermal growth factor (EGFR) receptors and vascular epithelial growth factor (VEGF) receptors the dermatologic manifestations of targeted agents and an introduction to radioimmunotherapy a treatment that has the ability to combine targeted agents directly with radiotherapy. The second half of the book focuses on specific disease sites, including malignant gliomas, head and neck, lung, pancreatic, cervical, and endometrial cancers.

Biologically targeted agents promise to be the next significant breakthrough in cancer therapy. Written by leading experts in the field,Combining Targeted Biological Agents with Radiotherapy is a comprehensive evaluation of the entire field.

"

Recenzijas

The book was written to 'review both the basic science and current clinical status of combining targeted biological agents with radiotherapy'... The authors are experts in the field of molecular targeting and clinical trials... comprehensive reviews of current studies and planned studies... well written.--Doody's Reviews

"Targeted Therapies: Definitions, Limitations, and Future Directions; Epidermal Growth Factor (EGFR) Receptors; Vascular Epithelial Growth Factor (VEGF) Receptors; Dermatologic Manifestations of Targeted Therapies; Dermatologic Manifestations of Targeted Therapies; Radiolabelled Monoclonal Antibody Therapies; Targeted Therapies in Malignant Gliomas; Targeted Therapies in Head and Neck Cancer; Targeted Therapies in Lung Cancer; Targeted Therapies in Pancreatic Cancer; Targeted Therapies in Cervical Cancer; Targeted Therapies in Endometrial Cancer."
William Small, Jr, MD is Professor of Radiation Oncology and Vice-Chairman of the Department of Radiation Oncology at Northwestern University. He is the Associate Medical Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and serves on the editorial board of the American Journal of Hematology/Oncology Review and Cancer News.